CompletedNot applicableNCT02100371

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Studying Gorlin syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University Health Network, Toronto
Principal Investigator: Lillian Siu, M.D.
Princess Margaret Cancer Centre
Intervention: BMS-833923(drug)
Enrollment: 2 enrolled
Eligibility: 18 years · FEMALE
Timeline: 2014 – 2017

Study locations (1)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02100371 on ClinicalTrials.gov

Other trials for Gorlin syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT06050122
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.

See all trials for Gorlin syndrome →

← Back to all trials